Wall Street Experts
ver. ZuMIgo(08/25)
Verve Therapeutics, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 24
EBIT TTM (mln): -227
index |
0 |
1 |
2 |
3 |
4 |
5 |
Rok finansowy |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
2 |
12 |
32 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
inf% |
505.8% |
175.0% |
Marża brutto |
-inf% |
-inf% |
-inf% |
-245.7% |
53.6% |
100.0% |
EBIT (mln) |
-14 |
-41 |
-87 |
-166 |
-223 |
-229 |
EBIT Δ r/r |
0.0% |
197.8% |
114.3% |
90.3% |
34.7% |
2.5% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
-8536.2% |
-1897.6% |
-707.2% |
Koszty finansowe (mln) |
0 |
0 |
0 |
-8 |
0 |
0 |
EBITDA (mln) |
-14 |
-39 |
-87 |
-163 |
-218 |
-229 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
-8391.7% |
-1851.2% |
-707.2% |
Podatek (mln) |
-0 |
-0 |
-2 |
0 |
0 |
0 |
Zysk Netto (mln) |
-19 |
-46 |
-119 |
-157 |
-200 |
-199 |
Zysk netto Δ r/r |
0.0% |
139.5% |
160.5% |
32.7% |
27.1% |
-0.7% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
-8108.6% |
-1701.5% |
-614.6% |
EPS |
-0.39 |
-0.94 |
-2.45 |
-2.91 |
-3.12 |
-2.36 |
EPS (rozwodnione) |
-0.39 |
-0.94 |
-2.45 |
-2.91 |
-3.12 |
-2.35 |
Ilośc akcji (mln) |
48 |
48 |
49 |
54 |
64 |
84 |
Ważona ilośc akcji (mln) |
48 |
48 |
49 |
54 |
64 |
85 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |